Singapore, Oct. 12 -- Everest Medicines announced on June 26, 2026, that China's National Medical Products Administration (NMPA) accepted the Biologics License Application (BLA) for LEROCHOL (lerodalcibep), a third-generation PCSK9 inhibitor, for subcutaneous use as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The on-schedule acceptance underscores the Company's disciplined execution of its clinical and regulatory strategy, and marks another key R&D milestone for 2026.

LEROCHOL is a novel, third-generation small recombinant fusion protein therapeutic agent comprised of a proprotein convertase subtilis...